Efficacy and safety of Shufeng Jiedu Capsule in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis
- PMID: 33429809
- PMCID: PMC7793378
- DOI: 10.1097/MD.0000000000024198
Efficacy and safety of Shufeng Jiedu Capsule in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis
Abstract
Background: With the outbreak of novel coronavirus, the treatment of respiratory diseases has been promoted. In particular, many traditional Chinese medicines, including Chinese patent medicines, have been found to be effective in the treatment of respiratory illness in China. chronic obstructive pulmonary disease (COPD) is one of most common respiratory condition. It is predicted that COPD will be become the third frequent cause of death by 2030. The aim of this study is to assess the efficacy and safety of Shufeng Jiedu Capsule in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Methods: According to the search strategy, randomized controlled trials (RCTs) of Shufeng Jiedu Capsule in the treatment of AECOPD were obtained from Cochrane Library, MEDLINE, Embase, CNKI, VIP, CBM, and WANGFANG. Studies were screened according to inclusion and exclusion criteria, and the Cochrane risk bias assessment tool was used to assess the quality of the study. Meta-analysis was performed using Revman 5.4 software. Finally, the evidence level of the results will be evaluated.
Results: The purpose of this study was to evaluate the efficacy and safety of Shufeng Jiedu Capsule in the treatment of AECOPD, and to provide basis for clinical rational drug use.
Conclusion: Our research results of this study could provide reference for clinical decision-making and guiding development in the future COPD patient.
Inplasy registration number: INPLASY2020120062.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Similar articles
-
Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis.BMC Complement Med Ther. 2020 May 24;20(1):151. doi: 10.1186/s12906-020-02924-5. BMC Complement Med Ther. 2020. PMID: 32448238 Free PMC article.
-
[Overview of systematic reviews of Shufeng Jiedu Capsules].Zhongguo Zhong Yao Za Zhi. 2022 Feb;47(4):1103-1113. doi: 10.19540/j.cnki.cjcmm.20210712.501. Zhongguo Zhong Yao Za Zhi. 2022. PMID: 35285211 Review. Chinese.
-
Efficacy and safety of Shufeng Jiedu capsule for coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta-analysis.Medicine (Baltimore). 2020 Aug 7;99(32):e21615. doi: 10.1097/MD.0000000000021615. Medicine (Baltimore). 2020. PMID: 32769921 Free PMC article.
-
[Systematic review and Meta-analysis of efficacy and safety of Shufeng Jiedu Capsules in treatment of influenza].Zhongguo Zhong Yao Za Zhi. 2023 Nov;48(22):6216-6224. doi: 10.19540/j.cnki.cjcmm.20230804.501. Zhongguo Zhong Yao Za Zhi. 2023. PMID: 38114228 Chinese.
-
Efficacy and safety of Shufeng Jiedu capsule in the treatment of COVID-19: A protocol for systematic review and meta analysis.Medicine (Baltimore). 2020 Dec 11;99(50):e23293. doi: 10.1097/MD.0000000000023293. Medicine (Baltimore). 2020. PMID: 33327256 Free PMC article.
Cited by
-
Study on basic and clinical application of Shufeng Jiedu Capsule in treating respiratory tract infection.Chin Med. 2023 Apr 25;18(1):45. doi: 10.1186/s13020-023-00749-1. Chin Med. 2023. PMID: 37098552 Free PMC article. Review.
-
Effects of acetylcysteine on micro-inflammation and pulmonary ventilation in chronic obstructive pulmonary disease exacerbation.World J Clin Cases. 2024 Jun 26;12(18):3482-3490. doi: 10.12998/wjcc.v12.i18.3482. World J Clin Cases. 2024. PMID: 38983436 Free PMC article.
-
Effects of Cardiopulmonary Rehabilitation Promotion Mode Intervention Combined with Oxygen Therapy on Cardiopulmonary Function and Blood Gas Analysis Indexes of COPD Patients with Cor Pulmonale.J Healthc Eng. 2022 Mar 26;2022:8495996. doi: 10.1155/2022/8495996. eCollection 2022. J Healthc Eng. 2022. Retraction in: J Healthc Eng. 2023 Oct 4;2023:9810235. doi: 10.1155/2023/9810235. PMID: 35378941 Free PMC article. Retracted.
References
-
- World Health Organization. The top 10 causes of death. Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death 24 May 2018.
-
- Global Burden of Disease 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545–602. - PMC - PubMed
-
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2020. goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_W... (accessed prior to 3 April 2020).
-
- Global Initiative for Chronic Obstructive Lung Disease. GOLD 2019 Global strategy for the diagnosis, management, and prevention of COPD. goldcopd.org/(accessed 5 May 2019).
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical